Our drug discovery engine

Buloxibutid (C21) is our pathfinder with potential to unlock a new class of drugs – Angiotensin II Type 2 receptor Agonists (ATRAGs). As a first-in-class orally administered ATRAG, buloxibutid binds to and activates the AT2 receptor, thereby stopping disease progression and restoring function.

Based on extensive preclinical documentation, the localization of the receptor in man as well as accumulating clinical data, stimulating the AT2 receptor may be beneficial in a wide range of diseases.

To fully exploit these opportunities, Vicore is developing new AT2 receptor agonists with improved properties and longer patent protection, making it possible to address a broad range of indications including non-orphan diseases.

A close collaboration with Emeriti Bio and HaLaCore Pharma, two experienced chemistry groups with unique knowledge of AT2 receptor chemistry, has generated a series of novel small molecules where the most promising ones will be developed further. The approach of parallel development of several compounds increases the chances of success and shortens the time to clinic.